Navigation Links
Sutro Announces Newly Formed Scientific Advisory Board
Date:1/7/2012

SAN FRANCISCO, Jan. 7, 2012 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its newly formed scientific advisory board (SAB).  Prof. Wells will serve as Chairman of the SAB.

"We have brought together two leading scientific experts in the field of protein engineering to provide valuable insight and perspective as we advance Sutro's therapeutic pipeline and expand Sutro's collaborative work," said William Newell, chief executive officer of Sutro Biopharma. "Prof. Wells brings a depth of expertise in protein engineering that will be indispensable for our continued innovation and growth. Prof. Swartz is a leading expert in the field of cell-free protein synthesis, and Sutro's biochemical protein synthesis technology platform is based on his research."

Prof. Wells is Harry Wm. and Diana V. Hind Professor in pharmaceutical sciences and director of the Small Molecule Discovery Center at the University of California, San Francisco (UCSF). His research focuses on the design of proteins and small molecules that trigger cellular processes in order to better understand and treat cancer and inflammation. Prof. Wells has over 20 years of industry experience, having founded Sunesis Pharmaceuticals, where he served as president and chief scientific officer. He was previously a founding scientist in Genentech's Department of Protein Engineering. He received his undergraduate degree from University of California, Berkeley, and his Ph.D. from Washington State University. Prof. Wells authored and co-authored numerous scientific publications.

"Sutro's technology has the ability to incorporate non-natural amino acids in every possible position and rapidly test these proteins," said Prof. Wells. "This is a novel protein engineering technology with unlimited potential which may ultimately define how drugs are developed in the future, and I am looking forward to working closely with Sutro's management as a scientific advisor."

Prof. Swartz, a leading expert in the field of cell-free protein synthesis, is a director and founder of Sutro Biopharma. He holds the James H. Clark Professorship in the School of Engineering at Stanford University and is a professor in the departments of bioengineering and chemical engineering. Prof. Swartz is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. He received his undergraduate degree in chemical engineering from the South Dakota School of Mines and his graduate degree from the Massachusetts Institute of Technology. Prof. Swartz is an author and a co-author on numerous scientific publications dealing with protein expression and advancement of cell-free protein production technology.

"I am delighted to expand my involvement with Sutro through the appointment as scientific advisor," said Prof. Swartz. "Sutro has made tremendous progress within the past year, and the scientific advisory board will be tasked with helping to guide Sutro's management as they work to expand the company's proprietary pipeline as well as the projects with current and new partners."

About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches, and are beyond what can be envisioned with current (cell-based) expression technologies. Sutro's biochemical synthesis technology, which underpins these therapeutics, allows the rapid and systematic exploration of many protein drug variants to identify drug candidates. Our make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks. Once identified, production of these protein drug candidates can be rapidly and predictably scaled up to commercial levels. In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies in the discovery and development of novel protein therapeutics.

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)
david.schull@russopartnersllc.com
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
2. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
3. AnaptysBio Announces New Strategic Antibody Discovery
4. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
5. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
6. AtheroNova Announces a New Board Member
7. RSB Spine, LLC Announces 2011 Revenue Growth
8. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
9. Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
10. Verify Brand™ Announces the Release of VB Enterprise 4.0
11. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... New York , May 6, 2016 ... Market Research " Molecular Diagnostic Market for Group A Streptococcus ... Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023 ... for group A streptococcus (GAS) nucleic acid (NA) test products ... is projected to expand at a CAGR of 11.6% from ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Office has granted two additional patents, U.S. Patent Nos. 9,322,133 and 9,322,134, to ... processes for making nanocellulose as well as hydrophobic nanocellulose compositions. In addition ...
(Date:5/4/2016)... ... 04, 2016 , ... Proove Biosciences, Inc. , the commercial and research ... McGill University . The partnership is designed to advance research in pain genetics in ... in pain. With the new agreement, researchers at Proove Biosciences are able to collaborate ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... in biotechnology to help treat hormonal and stress related hair loss. With patent-pending ... the hearts of key opinion leaders in the medical and salon channels nationwide. ...
Breaking Biology Technology:
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
Breaking Biology News(10 mins):